SWOG clinical trial number
SWOG-9413
Phase II Treatment with Etoposide (E), Leucovorin (L), 5-Fluorouracil (F) and Interferon Alpha 2b (I), (ELFI) + G-CSF for Locally Advanced or Recurrent Pancreatic Adenocarcinoma
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Phase II Treatment with Etoposide (E), Leucovorin (L), 5-Fluorouracil (F) and Interferon Alpha 2b (I), (ELFI) + G-CSF for Locally Advanced or Recurrent Pancreatic Adenocarcinoma
Activated
05/01/1995
Closed
03/15/1996
Research committees
Gastrointestinal Cancer
Publication Information Expand/Collapse
2014
PMid: PMID24914040 | PMC number: PMC4296727
2000
A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: A Southwest Oncology Group study (SWOG-9413)
Other Clinical Trials
SWOG Clinical Trial Number
S2303
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2107
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
100%
Open
Phase